Nadofaragene Firadenovec Clinical Trials (2026): 6 Studies for Bladder Cancer & CIS

Where to Participate: All Nadofaragene Firadenovec Trial Sites in the U.S. (101 sites across 29 states)

Every actively recruiting Nadofaragene Firadenovectrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Nadofaragene Firadenovec clinical trials at a glance: phase × recruitment status

Recruiting Nadofaragene Firadenovec clinical trials (5)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Nadofaragene Firadenovec clinical trials by indication

Nadofaragene Firadenovec pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Terminated and withdrawn Nadofaragene Firadenovec trials (1)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

• NCT06390111withdrawnA Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

All Nadofaragene Firadenovec trials (6)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Nadofaragene Firadenovec clinical trials: frequently asked questions

How many Nadofaragene Firadenovec clinical trials are there?

6 Nadofaragene Firadenovec clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants.

Are Nadofaragene Firadenovec clinical trials recruiting in 2026?

Yes — 4 Nadofaragene Firadenovec trials are actively recruiting in 2026, with 101 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Nadofaragene Firadenovec being studied for?

Nadofaragene Firadenovec is being studied for Bladder Cancer, CIS, Intermediate Risk Non-Muscle Invasive Bladder Cancer, Low-grade Upper Tract Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma and 5 more. The trials are grouped by indication on this page.

What phase is Nadofaragene Firadenovec in?

Nadofaragene Firadenovec clinical trials span 1 Phase 4, 3 Phase 3, 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Nadofaragene Firadenovec clinical trials?

The lead sponsor across the most Nadofaragene Firadenovec trials is Ferring Pharmaceuticals, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Nadofaragene Firadenovecas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.